Document Detail


Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
MedLine Citation:
PMID:  3257716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of these studies was to compare local and systemic human lymphokine activated killer (LAK) and natural killer (NK) cytotoxicity and to determine its modulation by the systemic administration of recombinant interleukin-2 (rIL-2). After preoperative systemic rIL-2, we extracted tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocytes (PBL) from patients with pulmonary tumors and compared pre- and posttreatment spontaneous NK activity and their response to in vitro rIL-2. Spontaneous TIL NK activity was increased in patients receiving 15,000 units/kg rIL-2 preoperatively [6.6 lytic units (LU)] compared to those receiving 1,000-10,000 units/kg (0.8 LU) or no rIL-2 (1.4 LU). After 3 days incubation with 1,000 units/ml rIL-2, TIL NK cytotoxic activity was increased in patients receiving 15,000 units/kg rIL-2 (65.4 LU) compared to those receiving 1,000-10,000 units/kg (6.0 LU) or no treatment (24.9 LU). Spontaneous TIL LAK activity was low overall (1.1 LU) with the exception of two patients receiving 15,000 units/kg who had 3.1 and 3.7 LU spontaneously. TIL LAK precursor activity was only slightly increased in patients receiving 1,000-10,000 units/kg rIL-2, whereas those receiving 15,000 units/kg rIL-2 had an average of 22.8 LU. Systemic rIL-2 also increased spontaneous PBL NK activity. Reincubation of PBL obtained at time of surgery or 3 days after discontinuing systemic rIL-2 resulted in significant increases in cytotoxic response to in vitro rIL-2 compared to pre-IL-2 in vitro responses. Systemic rIL-2 had no effect on spontaneous PBL LAK activity. Thus, the immunosuppressive tumor environment can be partially reversed with 15,000 units/kg systemic rIL-2. Higher doses of systemic rIL-2 also increased spontaneous PBL NK activity at time of surgery and 3 days after discontinuing rIL-2. Both TIL and PBL inducible cytotoxicity were boosted in vitro following higher doses of systemic rIL-2.
Authors:
T M Anderson; Y Ibayashi; Y Tokuda; S D Colquhoun; E C Holmes; S H Golub
Related Documents :
14712396 - Dose and frequency of interferon treatment matter--incomin and optims.
11142476 - A phase i-ii study of 9-cis retinoic acid and interferon-alpha2b in patients with advan...
8136946 - Phase ib trial of the effect of peritumoral and intranodal injections of interleukin-2 ...
18985796 - Pharmacokinetic properties of a 40 kda branched polyethylene glycol-modified form of co...
475106 - Cyanide intoxication in sheep: enhancement of efficacy of sodium nitrite, sodium thiosu...
8641666 - Single-dose and 13-week repeated-dose neurotoxicity screening studies of chlorpyrifos i...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer research     Volume:  48     ISSN:  0008-5472     ISO Abbreviation:  Cancer Res.     Publication Date:  1988 Mar 
Date Detail:
Created Date:  1988-03-28     Completed Date:  1988-03-28     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  2984705R     Medline TA:  Cancer Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1180-3     Citation Subset:  IM    
Affiliation:
Division of Surgical Oncology, John Wayne Cancer Clinic, Jonsson Comprehensive Cancer Center, UCLA School of Medicine 90024-1782.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Interleukin-2 / pharmacology*
Killer Cells, Natural / drug effects*
Lymphocytes / immunology*
Lymphokines / pharmacology*
Neoplasms / immunology*
Recombinant Proteins / pharmacology
Grant Support
ID/Acronym/Agency:
CA 12582/CA/NCI NIH HHS; CA 44532/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Interleukin-2; 0/Lymphokines; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant inte...
Next Document:  Potentiation by a biscoclaurine alkaloid, cepharanthine, of the toxicity of conjugates of epidermal ...